Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
← catalyst calendarNCT06040541 · readout in 133 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
604estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Solid Tumors
Interventions
- Drug: RMC-9805
- Drug: RMC-6236
Primary outcomes
what the primary-completion date above is the date OFAdverse events
measured Up to 3 years
Dose Limiting Toxicities
measured 21 days
Publications
- PMID 40705880 — linked by the registry
- PMID 40056080 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed